- Report
- April 2026
- 450 Pages
Global
From €4525EUR$5,000USD£3,862GBP
- Clinical Trials
- May 2026
- 450 Pages
Global
From €4525EUR$5,000USD£3,862GBP
- Report
- July 2026
- 115 Pages
Global
From €5295EUR$5,850USD£4,518GBP
- Report
- May 2026
- 350 Pages
Global
From €4479EUR$4,949USD£3,822GBP
- Report
- July 2025
Global
From €16286EUR$17,995USD£13,899GBP
- Report
- July 2026
- 160 Pages
Global
From €3756EUR$4,150USD£3,205GBP
- Report
- April 2026
- 160 Pages
Global
From €3005EUR$3,320USD£2,564GBP
€3756EUR$4,150USD£3,205GBP
- Report
- April 2026
- 160 Pages
Global
From €3005EUR$3,320USD£2,564GBP
€3756EUR$4,150USD£3,205GBP
- Report
- October 2025
- 160 Pages
Global
From €2860EUR$3,160USD£2,441GBP
€3575EUR$3,950USD£3,051GBP
- Report
- December 2025
- 150 Pages
Global
From €4389EUR$4,850USD£3,746GBP
- Report
- November 2025
- 150 Pages
Global
From €4389EUR$4,850USD£3,746GBP
- Report
- August 2025
- 167 Pages
Global
From €4389EUR$4,850USD£3,746GBP
- Report
- February 2026
- 193 Pages
Global
From €4389EUR$4,850USD£3,746GBP
- Report
- July 2026
- 50 Pages
Global
From €2398EUR$2,650USD£2,047GBP
- Report
- July 2026
- 50 Pages
Global
From €2398EUR$2,650USD£2,047GBP
- Report
- August 2025
- 200 Pages
United States
From €2254EUR$2,490USD£1,923GBP
- Report
- October 2025
- 90 Pages
Europe
From €2941EUR$3,250USD£2,510GBP
- Report
- September 2025
- 90 Pages
North America
From €2941EUR$3,250USD£2,510GBP
- Report
- September 2025
- 60 Pages
United States
From €2308EUR$2,550USD£1,970GBP
- Report
- April 2026
- 231 Pages
United States
From €4389EUR$4,850USD£3,746GBP

The Pancreatic Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat pancreatic cancer. Pancreatic cancer is a type of cancer that affects the pancreas, an organ located in the abdomen. It is a particularly aggressive form of cancer, and is often difficult to treat.
Pancreatic cancer drugs are designed to target the cancer cells and stop their growth. They can be used alone or in combination with other treatments, such as chemotherapy or radiation. Commonly used drugs include gemcitabine, capecitabine, and erlotinib.
The Pancreatic Cancer Drugs market is highly competitive, with many companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, Roche, and Novartis. Show Less Read more